# OnCo record paper-topaz-1-three-year-survival-j-hepatol-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-topaz-1-three-year-survival-j-hepatol-2025" ;
  schema:name "Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study"@en ;
  schema:description "Three and a half years on, adding durvalumab to chemotherapy for advanced bile duct and gallbladder cancer still showed a survival edge, and about one in seven patients were alive at three years compared with one in fourteen on chemotherapy alone."@en ;
  schema:url <https://onco.cc/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.jhep.2025.05.003>, <https://pubmed.ncbi.nlm.nih.gov/40381735/>, <https://clinicaltrials.gov/study/NCT03875235> ;
  onco:tag "gallbladder-evidence" ;
  schema:sameAs <https://doi.org/10.1016/j.jhep.2025.05.003> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Oh DY, He AR, Qin S, et al." ;
  onco:related <https://onco.cc/key-papers/paper-topaz-1-nejm-evidence-2022/>, <https://onco.cc/pairings/gemcis-plus-io-btc/> ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/os/> ;
  onco:trials <https://onco.cc/trials/topaz-1/> ;
  onco:people <https://onco.cc/people/juan-valle/> .